The B cell receptor (BCR) pathway inhibitors in CLL have shown high efficacy in the cases with poor chromosomal aberrations such as Del (17p) or p53 mutation, known to acquire resistance to standard chemotherapy. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.